BGNE - BeiGene, Ltd.
| Previous Close | 124.11 |
| Open | 125.27 |
| Bid | 110.47 x 800 |
| Ask | 132.00 x 1300 |
| Day's Range | 124.38 - 129.05 |
| 52 Week Range | 77.54 - 220.10 |
| Volume | 344,705 |
| Avg. Volume | 295,960 |
| Market Cap | 7.388B |
| Beta (3Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.11 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 210.07 |
- GlobeNewswire•2 days ago
Detailed Research: Economic Perspectives on BeiGene, Costco Wholesale, Rogers, Advance Auto Parts, Celcuity, and Harris — What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Reuters•9 days ago
BRIEF-Beigene Announces Updated Results From Phase 1 Clinical Trial Of Zanubrutinib
Oct 12 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES UPDATED RESULTS FROM PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA * BEIGENE LTD - FIRST U.S. NDA FILING FOR ...
- GlobeNewswire•9 days ago
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. and BEIJING, China, Oct. 12, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Reuters•10 days ago
BRIEF-MEI Pharma And Beigene Announce Clinical Collaboration
Oct 11 (Reuters) - Beigene Ltd: * MEI PHARMA AND BEIGENE ANNOUNCE CLINICAL COLLABORATION TO EVALUATE ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES * MEI PHARMA INC - STUDY ...
- PR Newswire•10 days ago
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies. "We are excited to be working with BeiGene to explore the potential of ME-401 in combination with zanubrutinib," said Robert Mass, M.D., chief medical officer of MEI Pharma.
- Reuters•11 days ago
BRIEF-Beigene Announces National Reimbursement Inclusion Of Vidaza® (Azacitidine For Injection) By The State Medical Insurance Administration In China
Oct 10 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES NATIONAL REIMBURSEMENT INCLUSION OF VIDAZA® (AZACITIDINE FOR INJECTION) BY THE STATE MEDICAL INSURANCE ADMINISTRATION IN CHINA * BEIGENE SAYS VIDAZA ...
- GlobeNewswire•11 days ago
BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China
BEIJING, China and CAMBRIDGE, Mass., Oct. 10, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•12 days ago
BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings
CAMBRIDGE, Mass. and BEIJING, China, Oct. 08, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- GlobeNewswire•19 days ago
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on September 28, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 58,641 American Depositary Shares to 195 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- Investopedia•24 days ago
3 Biotechs Poised for 10% Gains
Technical analysis suggests that Acadia Pharmaceuticals Inc. ( ACAD), BeiGene Ltd. ( BGNE) and Intercept Pharmaceuticals Inc. ( ICPT) are three such stocks that could see the significant gains. Acadia shares have skyrocketed higher over the past few weeks and are trading around a technical resistance level at $21.50. Should the stock be able to rise above that level of resistance, the shares could rally by 13% to a price of $24, from its current price of around $21.40.
- GlobeNewswire•26 days ago
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. and BEIJING, China, Sept. 25, 2018 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and.
- Reuters•29 days ago
BRIEF-Beigene Announces Preliminary Results From The Phase 1 Clinical Trial Of Zanubrutinib
Sept 21 (Reuters) - Beigene Ltd: * BEIGENE ANNOUNCES PRELIMINARY RESULTS FROM THE PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN CHINESE PATIENTS WITH B-CELL LYMPHOMA AT ANNUAL MEETING OF THE CHINESE SOCIETY ...
- GlobeNewswire•29 days ago
BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented preliminary results from the Phase 1 trial of its investigational BTK inhibitor zanubrutinib in Chinese patients with B-cell lymphoma in an oral presentation at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China. “We continue to be encouraged by clinical data on zanubrutinib, including these results, which we believe support its broad global clinical development.
- GlobeNewswire•last month
BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, presented clinical data on tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with lung cancers, in two oral presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China. “Advanced lung cancer is one of our focus areas for development of tislelizumab, where we hope to have an impact on the way patients are treated both in China and worldwide. This complex and difficult-to-treat disease has proven to be susceptible to treatment with immunotherapies,” commented Amy Peterson, M.D., Chief Medical Officer, Immuno-Oncology, at BeiGene.
- Reuters•last month
BRIEF-Beigene Presents Preliminary Results On Tislelizumab
Sept 20 (Reuters) - Beigene Ltd: * BEIGENE PRESENTS PRELIMINARY RESULTS ON ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR-DEFICIENT SOLID TUMORS AT ...
- GlobeNewswire•last month
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, presented preliminary clinical data from Chinese patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors enrolled in an ongoing Phase 1/2 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Xiamen, China.
- Reuters•last month
BRIEF-Beigene Selects GE Healthcare's Biologics Factory To Boost Manufacturing Capacity
Sept 18 (Reuters) - Beigene Ltd: * BEIGENE SELECTS GE HEALTHCARE’S OFF-THE-SHELF BIOLOGICS FACTORY TO BOOST ITS MANUFACTURING CAPACITY FOR CANCER DRUGS * GENERAL ELECTRIC CO - FIRST PHASE OF KUBIO FACILITY ...
- GlobeNewswire•last month
BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology
BEIJING, China and CAMBRIDGE, Mass., Sept. 16, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology ...
- The Wall Street Journal•last month
[$$] SpringWorks Joins BeiGene in Cancer Drug Collaboration
Ltd. are teaming up to find out if a combination of two cancer treatments can help patients. Inc., and a plan to develop treatments for patients who lack good treatment options. The company has the rights to four clinical-stage Pfizer drugs.
- Reuters•last month
BRIEF-Beigene And Springworks Therapeutics Collaborate To Evaluate Targeted Combination Therapy In Advanced Solid Tumors
Sept 6 (Reuters) - Beigene Ltd: * BEIGENE AND SPRINGWORKS THERAPEUTICS ENTER INTO GLOBAL CLINICAL COLLABORATION TO EVALUATE TARGETED COMBINATION THERAPY IN ADVANCED SOLID TUMORS * BEIGENE LTD - BEIGENE'S ...
- Business Wire•last month
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene’s investigational RAF dimer inhibitor, lifirafenib (BGB-283) and SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors. Under the terms of the agreement, BeiGene will be responsible for administering the Phase 1b clinical trial that is expected to commence during the first quarter of 2019 in patients with advanced solid tumors that harbor RAS, RAF mutations and other MAPK pathway aberrations, with all costs of the clinical studies and governance responsibilities to be shared equally among both parties.
- GlobeNewswire•2 months ago
BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto
CAMBRIDGE, Mass. and BEIJING, China, Sept. 05, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology ...
- GlobeNewswire•2 months ago
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on August 31, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 46,896 American Depositary Shares (ADSs) and non-qualified share options to purchase an aggregate of 6,108 ADSs to 174 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan. The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- GlobeNewswire•2 months ago
BeiGene to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass., and BEIJING, China, Sept. 04, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology ...
- GlobeNewswire•2 months ago
BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China
HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the National Medical Products Administration of China (NMPA, formerly known as CFDA or CDA) has accepted the new drug application (NDA) for tislelizumab, an investigational anti-PD-1 antibody, as a potential treatment for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL). “The acceptance of our first NDA for tislelizumab represents an important milestone for BeiGene and for Chinese patients with Hodgkin’s lymphoma.